

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities or an invitation to enter into any agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.

*The material contained in this announcement is not for distribution or circulation, directly or indirectly, in or into the United States. This announcement is solely for the purpose of reference and does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the securities offer are being offered and sold only outside the United States in offshore transaction in compliance with Regulation S under the Securities Act.*

**NOTICE OF LISTING ON
THE STOCK EXCHANGE OF HONG KONG LIMITED**

HUAXIN PHARMACEUTICAL (HONG KONG) CO., LIMITED

(Incorporated in Hong Kong with limited liability)

US\$56,000,000 6.80 per cent. Guaranteed Notes due 2021 (the “New Notes”) consolidated and form a single series with US\$150,000,000 6.80 per cent. Guaranteed Notes due 2021 issued on 15 March 2018 (the “Existing Notes”)

unconditionally and irrevocably guaranteed by



TAIZHOU HUAXIN PHARMACEUTICAL INVESTMENT CO., LTD.

(Incorporated in the People's Republic of China with limited liability)

(Stock Code: 4447)

Joint Global Coordinators

SPDB International

BNP Paribas

Guotai Junan International

Joint Bookrunners and Joint Lead Managers

SPDB International

BNP Paribas

Guotai Junan International

China Everbright Bank

Hong Kong Branch

Central Wealth Securities Investment Limited

China Securities Limited

Application has been made to The Stock Exchange of Hong Kong Limited for the listing of, and permission to deal, in the New Notes by way of debt issues to professional investors (as defined in Chapter 37 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange and in the Securities and Futures Ordinance (Cap. 571) of Hong Kong) only as described in the offering circular dated 26 March 2018. The listing and permission to deal in the New Notes is expected to become effective on 4 May 2018.

3 May 2018

As at the date of this announcement, the directors of the Issuer are Ms. Xia Nan and Ms. Wu Zhilan.

As at the date of this announcement, the directors of Taizhou Huaxin Pharmaceutical Investment Co., Ltd. are Mr. Shen Zhongjian, Mr. Hang Xiang, Ms. Xia Nan, Mr. Wang Jianhui and Ms. Wu Zhilan.